"The U.S. Food and Drug Administration today approved Vimizim (elosulfase alfa), the first FDA-approved treatment for Mucopolysaccharidosis Type IVA (Morquio A syndrome). Morquio A syndrome is a rare, autosomal recessive lysosomal storage disease "...
(pentetate calcium trisodium) Injection 1000 mg
For Intravenous or Inhalation Administration
Pentetate calcium trisodium injection contains the sodium salt of calcium diethylenetriaminepenta-acetate. Pentetate calcium trisodium is also known as trisodium calcium diethylenetriaminepenta-acetate and is commonly referred to as Ca-DTPA (pentetate calcium trisodium inj) . It has a molecular formula of Na3CaC14H18N3O10 and a molecular weight of 497.4 Daltons. It is represented by the following structural formula:
Ca-DTPA (pentetate calcium trisodium inj) is supplied as a clear, colorless, hyperosmolar (1260 mOsmol/kg) solution in a colorless ampoule containing 5 mL. The ampoule contents are sterile, non-pyrogenic and suitable for intravenous administration. Each mL of solution contains the equivalent of 200 mg pentetate calcium trisodium (obtained from 158.17 mg pentetic acid, 40.24 mg calcium carbonate and NaOH) in water for injection, USP. The pH of the solution is adjusted with NaOH and is between 7.3 - 8.3.
Last reviewed on RxList: 1/7/2009
This monograph has been modified to include the generic and brand name in many instances.
Additional Ca-DTPA Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.